CAR T cell therapy has altered the natural history of relapsed and/or refractory diffuse large B cell lymphoma (DLBCL). However, the availability of multiple products has created provider uncertainty regarding treatment selection and the need to balance toxicity and efficacy. In a retrospective analysis, the authors suggest that axicabtagene ciloleucel might be superior to tisagenlecleucel. However, several questions remain unresolved.
This is a preview of subscription content, access via your institution
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Hu, Z. H., Peter Gale, R. & Zhang, M. J. Direct adjusted survival and cumulative incidence curves for observational studies. Bone Marrow Transplant. 55, 538–543 (2020).
Khera, N. et al. Comparison of characteristics and outcomes of trial participants and nonparticipants: example of blood and marrow transplant clinical trials network 0201 trial. Biol. Blood Marrow Transplant. 21, 1815–1822 (2015).
Bachy, E. et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat. Med. 28, 2145–2154 (2022).
Brookhart, M. A. et al. Variable selection for propensity score models. Am. J. Epidemiol. 163, 1149–1156 (2006).
Bethge, W. A. et al. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. Blood 140, 349–358 (2022).
Gauthier, J. et al. Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL. Blood 139, 3722–3731 (2022).
Riedell, P. A. et al. Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B cell lymphomas. Transplant Cell Ther. 28, 669–676 (2022).
Oluwole, O. O. et al. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br. J. Haematol. 194, 690–700 (2021).
NICE. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years. nice.org.uk, https://www.nice.org.uk/guidance/ta554 (21 December 2022).
ICER. Leukemia and Lymphoma. icer.org https://icer.org/assessment/leukemia-and-lymphoma-2018 (March 2018).
R.T.M. has acted as a consultant and/or adviser of Artiva Therapeutics, Bristol-Myers Squibb/Celgene, CRISPR Therapeutics, Incyte, Kite and Novartis and has received research funding from BMS and Novartis. J.G. has acted as a consultant and/or adviser of Janssen, Kite Pharma, Legend Biotech and MorphoSys and has received research funding from Angiocrine Bioscience, Celgene (a BMS company), Juno Therapeutics (a BMS company) and Sobi.
About this article
Cite this article
Maziarz, R.T., Gauthier, J. Clash of the titans: axi-cel versus tisa-cel for advanced-stage DLBCL. Nat Rev Clin Oncol 20, 5–6 (2023). https://doi.org/10.1038/s41571-022-00711-4